Lead Product(s) : Dotinurad,Allopurinol
Therapeutic Area : Rheumatology
Study Phase : Phase I/ Phase II
Sponsor : Novo Holdings
Deal Size : $205.0 million
Deal Type : Series A Financing
Novo-Backed Crystalys Debuts With $205M to Tackle Gout
Details : The financing round will support the advancement of Phase 3 evaluating, FYU-981 (dotinurad), a next-generation, once daily oral, URAT1 inhibitor for the treatment of gout.
Product Name : FYU-981
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 30, 2025
Lead Product(s) : Dotinurad,Allopurinol
Therapeutic Area : Rheumatology
Highest Development Status : Phase I/ Phase II
Sponsor : Novo Holdings
Deal Size : $205.0 million
Deal Type : Series A Financing
Lead Product(s) : SAP-001
Therapeutic Area : Rheumatology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function
Details : SAP-001 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Gout.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 11, 2024
Lead Product(s) : SAP-001
Therapeutic Area : Rheumatology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IG3018
Therapeutic Area : Rheumatology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IG3018 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Hyperuricemia.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 15, 2024
Lead Product(s) : IG3018
Therapeutic Area : Rheumatology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dontinurad
Therapeutic Area : Rheumatology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia
Details : Dontinurad is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Gout.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 28, 2023
Lead Product(s) : Dontinurad
Therapeutic Area : Rheumatology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Recombinant Anti-IL-1 Humanized Monoclonal Antibody
Therapeutic Area : Rheumatology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Recombinant Anti-IL-1 Humanized Monoclonal Antibody is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Gout.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 20, 2022
Lead Product(s) : Recombinant Anti-IL-1 Humanized Monoclonal Antibody
Therapeutic Area : Rheumatology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Genakumab
Therapeutic Area : Rheumatology
Study Phase : Phase I/ Phase II
Sponsor : Huashan Hospital | Hainan General Hospital | Linyi People's Hospital | The Second Affiliated Hospital of Chongqing Medical University | Changhai Hospital | The First Affiliated Hospital with Nanjing Medical University | Shengjing Hospital | Affiliated Hos
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinical Study of Genakumab for Injection in Patients With Acute Gout
Details : Genakumab is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Gout.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 14, 2022
Lead Product(s) : Genakumab
Therapeutic Area : Rheumatology
Highest Development Status : Phase I/ Phase II
Sponsor : Huashan Hospital | Hainan General Hospital | Linyi People's Hospital | The Second Affiliated Hospital of Chongqing Medical University | Changhai Hospital | The First Affiliated Hospital with Nanjing Medical University | Shengjing Hospital | Affiliated Hos
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Rheumatology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections
Details : This drug candidate is currently being evaluated in phase I/ phase II clinical studies for the treatment of Arthritis, Infectious.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 07, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Rheumatology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ALN-XDH
Therapeutic Area : Rheumatology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate ALN-XDH in Healthy Subjects and Patients With Gout
Details : ALN-XDH is a Oligonucleotide drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Gout.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
February 25, 2022
Lead Product(s) : ALN-XDH
Therapeutic Area : Rheumatology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Rheumatology
Study Phase : Phase I/ Phase II
Sponsor : Mayo Clinic
Deal Size : Inapplicable
Deal Type : Inapplicable
Bacteriophage Therapy in Patients With Prosthetic Joint Infections
Details : This drug candidate is currently being evaluated in phase I/ phase II clinical studies for the treatment of Arthritis, Infectious.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 08, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Rheumatology
Highest Development Status : Phase I/ Phase II
Sponsor : Mayo Clinic
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : D-0120
Therapeutic Area : Rheumatology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
D-0120 Safety and PK/PD Study in China
Details : D-0120 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Hyperuricemia.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 23, 2019
Lead Product(s) : D-0120
Therapeutic Area : Rheumatology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable